14420
document
Treatment of peptic ulcer disease with furazolidone . Furazolidone ( FZ ) has been used in China as a treatment of peptic ulcer disease for about 20 years . Clinical and experimental studies suggest that it has good short-term and long-term effects on both human and animal ulcers . The ulcer healing rate is related to the dosage and course of treatment . The healing rate of a high dose , 2 week course is about 70-75 % and the relapse rate after 3 years is 9.5 % . The adverse reactions to FZ are not severe , and are well tolerated in most patients . However the mutagenic studies of several biological systems indicate that it has a mutagenic effect , but the mutagenic and carcinogenic effects on humans and animals remain questionable , because FZ has been biotransformed into other metabolites . The mechanisms of FZ in the treatment of peptic ulcer disease are not fully understood , perhaps partly due to the monoamine oxidase ( MAO ) inhibitory reaction and partly to the antibacterial activity to Helicobacter pylori ( HP ) . The long-term effects of FZ are still not clear .
14421
Intervention_Pharmacological
furazolidone . Furazolidone
14422
Outcome_Physical
peptic ulcer disease
14423
Outcome_Physical
peptic
14424
Outcome_Physical
animal ulcers .
14425
Outcome_Physical
ulcer healing
14426
Outcome_Other
tolerated
14427
Outcome_Other
mutagenic
14428
Outcome_Adverse-effects
carcinogenic
14429
Outcome_Physical
monoamine oxidase ( MAO ) inhibitory reaction
14430
Outcome_Physical
antibacterial activity to Helicobacter pylori
14431
Participant_Condition
peptic ulcer disease
14432
Participant_Condition
peptic ulcer disease
14433
Participant_Sex
human
14434
Participant_Condition
animal ulcers
14435
Participant_Condition
peptic ulcer disease